sorafenib has been researched along with genistein in 6 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (genistein) | Trials (genistein) | Recent Studies (post-2010) (genistein) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 7,423 | 204 | 2,311 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Caballero, E; García-Cárceles, J; Gil, C; Martínez, A | 1 |
| Banik, NL; Karmakar, S; Ray, SK; Roy Choudhury, S | 1 |
| Arias, A; Catania, VA; Ceballos, MP; Ciriaci, N; Ghanem, CI; Luquita, MG; Mottino, AD; Rigalli, JP; Ruiz, ML; Villanueva, SS | 1 |
| Abdel-Naim, AB; Badawy, NN; El-Ahwany, E; Khalifa, AE; Liu, AW; Tolba, MF; Youssef, MM; Zada, S | 1 |
1 review(s) available for sorafenib and genistein
| Article | Year |
|---|---|
Kinase Inhibitors as Underexplored Antiviral Agents.
Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses | 2022 |
5 other study(ies) available for sorafenib and genistein
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplifi
Topics: Angiogenesis Inducing Agents; Apoptosis; bcl-2-Associated X Protein; Benzenesulfonates; Caspase 3; Cell Cycle; Cell Proliferation; Cell Shape; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Drug Synergism; Flow Cytometry; Gene Amplification; Genistein; Humans; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neuroblastoma; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyridines; Signal Transduction; Sorafenib; Telomerase; Treatment Outcome; Tumor Suppressor Protein p53; Up-Regulation | 2010 |
Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genistein; Humans; Liver Neoplasms; Membrane Transport Proteins; MicroRNAs; Niacinamide; Phenylurea Compounds; Phytoestrogens; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Tumor Cells, Cultured | 2015 |
Novel combination of sorafenib and biochanin-A synergistically enhances the anti-proliferative and pro-apoptotic effects on hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Genistein; Hepatocytes; Humans; Inhibitory Concentration 50; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |